|
Session 183
Poster Abstracts
Detecting Acute/Incident Infection
Monday, 1-2:30 pm
Poster Hall |
988
 |
Detection of Individuals with Acute HIV-1 Infection with the ARCHITECT HIV Ag/Ab Combo Assay
Susan Eshleman*1, L Khaki1, E Piwowar-Manning1, L Johnson-Lewis1, O Laeyendecker1,2, A Vallari3, T Lukaszewska3, S Devare3, J Hackett Jr3, and the EXPLORE Study Team
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2NIAID, NIH, Bethesda, MD, US; and 3Abbott Diagnostics, Abbott Park, IL, US |
989
|
Detection of Acute HIV Infections Using a Fourth Generation Antigen/Antibody Assay
Pragna Patel*1, B Bennett2, T Sullivan3, M Parker3, P Sullivan4, and CDC AHI Study Group
1CDC, Atlanta, GA, US; 2Florida Bureau of Labs, Jacksonville, US; 3New York State Diagnostics HIV Lab, Albany, US; and 4Emory Univ Rollins Sch of Publ Hlth, Atlanta, GA, US |
| 990 |
Limitations of Rapid HIV Antibody Testing in a Population with High Incidence of HIV Infection
Joanne Stekler*1,2, P Swenson1,2, R Coombs1, J Dragavon1, C Brennan3, S Devare3, A Vallari3, P Swanson3, R Wood1,2, and M Golden1,2
1Univ of Washington, Seattle, US; 2Publ Hlth-Seattle & King County, WA, US; and 3Abbott Diagnostics, Abbott Park, IL, US |
991
|
Evaluation of the Abbott ARCHITECT Ag/Ab ComboŽ Assay, an Antigen/Antibody Combination Test: Implications for US HIV Testing Programs
Michele Owen*1, P Patel1, L Wesolowski1, A Vallari2, C Brennan2, S Devare2, and K Delaney1
1CDC, Atlanta, GA, US and 2Abbott Diagnostics, Abbott Park, IL, US |
| 992 |
A Clinical Study of Antigen/Antibody Rapid Testing for Acute HIV Infection
Christopher Pilcher*1, B Louie2, S Keating3, M Pandori2, F Fish4, T Keren4, M Lebedeva3, S Liska2, M Busch3, and F Hecht1
1Univ of California, San Francisco, US; 2San Francisco Publ Hlth Lab, CA, US; 3Blood Systems Res Inst, San Francisco, CA, US; and 4Inverness Med Innovations |
993
|
Ability of the Genprobe APTIMA HIV-1 RNA Qualitative Assay to Confirm Reactive Rapid HIV Screening Tests
James Heffelfinger*1, K Delaney1, M Owen1, D Candal1, S Kennedy1, A Uniyal2, P Kerndt2, and B Branson1
1CDC, Atlanta, GA, US and 2Los Angeles County Dept of Hlth Svcs, CA, US |
994
|
Comparison of 5 HIV Incidence Assays with the Less Sensitive Vironostika HIV Antibody Assay for Screening Subjects for A5217
Susan Fiscus*1, A Cachafeiro1, R Kshatriya1, S Napravnik1, M Owen2, S Keating3, M Busch3, S Little4, and C Hogan5,6
1Univ of North Carolina at Chapel Hill, US; 2CDC, Atlanta, GA, US; 3Blood Systems Res Inst, San Francisco, CA, US; 4Univ of California, San Diego, US; 5Columbia Univ, New York, NY, US; and 6Med Coll of Wisconsin, AIDS Resource Ctr of Wisconsin, Milwaukee, US |
995a
|
Derivation of HIV Incidence Assay "Window Periods" from Seroconverting Blood Donors in Countries with Diverse HIV Clades
Michael Busch*1,2, S Stramer3, M Vermeulen4, T Goncalez1,5, S Keating1, and R Remis6
1Blood Systems Res Inst, San Francisco, CA, US; 2Univ of California, San Francisco, US; 3American Red Cross, Gaithersburg, MD; 4South African Natl Blood Svc, Weltevreden Park; 5Fndn Pro-Sangue, Hemocentro of Sao Paulo, Brazil; and 6Univ of Toronto, Canada |
995b
|
Comparative Clinical Evaluation of the COBAS TaqScreen MPX Test with the COBAS AmpliScreen HIV-1 v1.5, HCV v.2.0, and HBV Tests Using High Risk Population and Seropositive Specimens
Y Ohhashi, A Pai, H Halait, and Rainer Ziermann*
Roche Molecular Systems, Pleasanton, CA, US |
|
